| Patent Number |
Title Of Patent |
Date Issued |
| 7115609 |
Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases |
October 3, 2006 |
| Compounds of formula (I) ##STR00001## in which R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7109231 |
Cyclohept[b]indole derivatives |
September 19, 2006 |
| A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock ##STR00001## |
| 7109229 |
Methods and compounds for treating proliferative diseases |
September 19, 2006 |
| The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I). ##STR00001## |
| 7105541 |
Naphthyl compounds, intermediates, compositions, and methods of use |
September 12, 2006 |
| The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use. |
| 7101891 |
Compounds and pharmaceutical compositions for inhibiting MRP1 |
September 5, 2006 |
| The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1 ##STR00001## |
| 7101843 |
Glucagon-like peptide-1 analogs |
September 5, 2006 |
| Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed. |
| 7101539 |
Use of LP82 to treat hematopoietic disorders |
September 5, 2006 |
| The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antago |
| 7093595 |
Portable medication inhalation kit |
August 22, 2006 |
| A portable kit (20) in which is conveniently retained the materials required for a user to pulmonarily delivery inhaleable medication. The kit (20) includes a carrying case (22) in which a plurality of individual doses (5) of an inhaleable medication are removably mounted. An inhaler |
| 7087635 |
3-substituted oxindole .beta.3 agonists |
August 8, 2006 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 7087626 |
Pyrrole derivatives as pharmaceutical agents |
August 8, 2006 |
| Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O |
| 7087578 |
Formulations and methods for treating hypercoagulable states |
August 8, 2006 |
| A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen. |
| 7084243 |
Glucagon-like peptide-1 analogs |
August 1, 2006 |
| Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed. |
| 7084170 |
Thiophene-amd thiazolesulfonamides as antineoplastic agents |
August 1, 2006 |
| The present invention provides antineoplastic compounds of the formula: ##STR00001## and antineoplastic methods. |
| 7081481 |
Excitatory amino acid receptor modulators |
July 25, 2006 |
| Compounds of the formula (I) in which: R.sup.1 is (CH.sub.2).sub.nY; n is 1 or 2; Y is NHSO.sub.2R.sup.2 or X.sup.1--W--X.sup.2--R.sup.3; X.sup.1 is O or NH; W is C.dbd.O, C.dbd.S, C.dbd.NH, or SO.sub.2; X.sup.2 is O or NH, provided that X.sup.1 and X.sup.2 are not both O; R.sup.2 is |
| 7078415 |
Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disor |
July 18, 2006 |
| Compounds of formula (I) ##STR00001## in which R, R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7071208 |
.beta..sub.3 Adrenergic agonists |
July 4, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity. |
| 7067510 |
Dihydro-dibenzo[b,e]oxepine based selective estrogren receptor modulators, compositions and meth |
June 27, 2006 |
| The present invention provides a compound of the formula (I) wherein R.sup.1 is --H, --OH, --O(C.sub.1 C.sub.4 alkyl), --OCOC.sub.6H.sub.5, --OCO(C.sub.1 C.sub.6 alkyl), or --OSO.sub.2(C.sub.2 C.sub.6 alkyl); R.sup.0, R.sup.2 and R.sup.3 are each independently --H, --OH, --O(C.sub.1 |
| 7064131 |
Compounds and methods for inhibiting MRP1 |
June 20, 2006 |
| The present invention relates to a compound of formula (I) which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1. ##STR00001## |
| 7056931 |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
June 6, 2006 |
| The current invention provides novel 2-substituted 1,2,3,4-tetrahydroquinolin-6-ols and derivatives thereof of the formula (I) (A); pharmaceutical compositions thereof, optionally in combination with estrogen or progestin; methods for inhibiting a disease associated with estrogen dep |
| 7053078 |
Serine protease inhibitors |
May 30, 2006 |
| Compounds of formula (I) ##STR00001## in which R.sub.2, X, Y, Cy, L and Lp(D).sub.n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders. |
| 7053065 |
Vitamin B12 and pemetrexed disodium combination therapies |
May 30, 2006 |
| A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent. |
| 7045628 |
Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydr |
May 16, 2006 |
| The present invention relates to a one-pot process for preparing a compound of formula I: I; by reacting a compound of formula II with a compound of formula III: in the presence of a suitable solvent, a suitable base, a palladium catalyst and a suitable ligand. |
| 7045545 |
Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists |
May 16, 2006 |
| The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4', R.sup.5, R.sup.5', and R.sup.12 are as described in the specification. ##STR00001## |
| 7041684 |
Selective .beta..sub.3 adrenergic agonists |
May 9, 2006 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta..sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides |
| 7041637 |
Echinocandin/carbohydrate complexes |
May 9, 2006 |
| A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of |
| 7038077 |
Prodrugs of excitatory amino acids |
May 2, 2006 |
| This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. |
| 7037932 |
Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors |
May 2, 2006 |
| There is provided a heretoaryloxy 3-substituted propanamine compound of formula (I): wherein A is selected from --O-- and --S--; X is selected from phenyl optionally substituted with up to 5 substituents selected from halo, C.sub.1 C.sub.4 alkyl and C.sub.1 C.sub.4 alkoxy, and thienyl |
| 7037921 |
Compounds and methods for inhibiting MRP1 |
May 2, 2006 |
| The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1. ##STR00001## |
| 7034045 |
Monofluoroalkyl derivatives |
April 25, 2006 |
| The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders. |
| 7033812 |
.beta.-secretase and modulation of .beta.-secretase activity |
April 25, 2006 |
| The invention concerns a novel .beta.-secretase, a method of partially purifying this novel .beta.-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel .beta.-secretase has an estimated molecul |
| 7026348 |
Indole sPLA2 inhibitors |
April 11, 2006 |
| A class of novel acylsulfonamide substituted indole compounds is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. |
| 7022674 |
Polypeptide compositions with improved stability |
April 4, 2006 |
| The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provi |
| 7012153 |
Process for preparing benzoic acids |
March 14, 2006 |
| An improved process for the preparation of 4[(2-piperidin-1-yl)ethoxy]benzoic acid derivatives, comprising reacting a haloalkyl amine of formula (III) with a compound of formula (IV) in the presence of a hydrated inorganic base in an appropriate solvent. |
| 7009060 |
2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as .beta..sub.3 agonists |
March 7, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 7001908 |
Arylpiperazines having activity at the serotonin 1A receptor |
February 21, 2006 |
| A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1.sub.A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms |
| 6998122 |
Protein C derivatives |
February 14, 2006 |
| Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type huma |
| 6992100 |
sPLA.sub.2 inhibitors |
January 31, 2006 |
| A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6992097 |
Growth hormone secretagogues |
January 31, 2006 |
| This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also |
| 6989261 |
Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of us |
January 24, 2006 |
| The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating |
| 6984756 |
Process for preparing biphenyl compounds |
January 10, 2006 |
| The present invention relates to a process for the preparation of a biphenyl compound comprising combining a phenyl boronic acid derivative with an halobenzene derivative in the presence of a suitable additive in a suitable organic solvent with a suitable catalyst and a suitable base. |
| 6984661 |
Urea linker derivatives for use as PPAR modulators |
January 10, 2006 |
| The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C.sub.1-C.sub.8 alkyl substituted C.s |
| 6983843 |
Container and a container accessory |
January 10, 2006 |
| The invention is particularly, although not exclusively, concerned with a protective container (1; 1') for fragile articles (100), such as bottles, vials or ampoules of fluid medicament. In one aspect, the protective container is provided with impact energy-absorbing structural features |
| 6982278 |
Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
January 3, 2006 |
| Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalk |
| 6977077 |
Method of increasing bone toughness and stiffness and reducing fractures |
December 20, 2005 |
| The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potenti |
| 6974831 |
sPLA2 inhibitors |
December 13, 2005 |
| A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6967201 |
Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
November 22, 2005 |
| The present invention provides serotonergic benzofurylpiperazines of Formula I: ##STR1##where: A is a piperazine of formula: ##STR2##and R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5', R.sup.6, R.sup.6', R.sup.7, R.sup.7', R.sup.8, and R.sup.8' are as described in the |
| 6965012 |
Flint polypeptide analogs |
November 15, 2005 |
| Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions wit |
| 6962928 |
Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast ca |
November 8, 2005 |
| The current invention provides methods for inhibiting osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis comprising administering to a patient in need thereof a compound of the formula: ##STR1## |
| 6960577 |
Combination therapy for treatment of refractory depression |
November 1, 2005 |
| Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed. |
| 6960564 |
Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
November 1, 2005 |
| Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the |
